SUBSCRIBE
SUBSCRIBE

Lyra Therapeutics

IN THE PRESS
Press Releases
Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
November 12, 2024
 · 
9 min read
Press Releases
Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis
October 15, 2024
 · 
4 min read
Press Releases
Lyra Therapeutics to Present Study Results for LYR-210 and LYR-220 in Two Presentations at the ARS and AAO-HNS Annual Meetings
September 30, 2024
 · 
3 min read
Press Releases
Lyra Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 15, 2024
 · 
15 min read
Business
Lyra Therapeutics Announces Cost-Cutting Measures to Preserve Capital
May 21, 2024
 · 
8 min read
Drug Development
Lyra Therapeutics Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic Rhinosinusitis
May 6, 2024
 · 
8 min read
Business
Lyra Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
April 30, 2024
 · 
11 min read
Genetown
Lyra Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 26, 2024
April 26, 2024
 · 
2 min read
Business
Lyra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
March 21, 2024
 · 
12 min read
Genetown
Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - March 01, 2024
March 1, 2024
 · 
2 min read
Load More
JOBS